Department of Pathology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh 202002, U.P., India.
Department of Pathology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh 202002, U.P., India.
Ann Diagn Pathol. 2020 Apr;45:151443. doi: 10.1016/j.anndiagpath.2019.151443. Epub 2019 Dec 13.
Cancer of uterine cervix is the most common cancer among Indian females. Surgery is the main modality of treatment along with radiation and chemotherapy depending upon clinical stage of the tumor and surgical findings. However, patients with advanced or recurrent disease have a poor survival despite the use of cisplatin-based combination chemotherapy. Hence, there is an increasing need for developing novel therapeutic target that can replace or be added to the current therapy for these patients. The present study was conducted to evaluate the presence of Her-2/neu expression. Two hundred cervical specimens were included in this study. These comprised cases with diagnosis of cervical intraepithelial neoplasia, squamous cell carcinoma, adenocarcinoma. HER-2/neu immunostaining was performed by using BioGenex monoclonal mouse anti-human HER-2/neu Receptor IgG1 antibody. Higher expression of HER-2/neu was noted in malignant lesions as compared to premalignant lesions. Intensity of staining also correlated with grade of malignant tumor, clinical stage and lymph node metastasis. The over-expression of HER-2/neu oncoprotein is found to be associated with poor prognosis, metastatic potential and aggressive biological behaviour.
宫颈癌是印度女性中最常见的癌症。手术是主要的治疗方式，根据肿瘤的临床分期和手术发现，结合放疗和化疗。然而，即使使用顺铂为基础的联合化疗，晚期或复发性疾病患者的生存仍然较差。因此，需要开发新的治疗靶点，以替代或补充这些患者的现有治疗方法。本研究旨在评估 Her-2/neu 表达的存在。本研究纳入了 200 例宫颈标本。这些标本包括宫颈上皮内瘤变、鳞状细胞癌和腺癌的病例。HER-2/neu 免疫染色采用 BioGenex 单克隆鼠抗人 HER-2/neu 受体 IgG1 抗体进行。与癌前病变相比，恶性病变中观察到更高的 HER-2/neu 表达。染色强度也与恶性肿瘤的分级、临床分期和淋巴结转移相关。HER-2/neu 癌蛋白的过表达与不良预后、转移潜能和侵袭性生物学行为有关。
